The company manufactures plastic packaging products like HDPE containers, PP closures, and liners for industrial use, and has recently expanded into disposable hygiene products including sanitary napkins and diapers.
The company operates in a highly fragmented and commoditized plastic packaging and hygiene market where competition is based primarily on price. While returns on equity appear high, the negative net margins and reliance on related-party sales suggest a lack of independent pricing power or brand-based competitive advantage.
Management has recently pivoted capital toward the hygiene sector by acquiring assets through bank auctions and raising funds via preferential allotments. While revenue growth is high, the lack of consistent profitability suggests that reinvested capital is not yet yielding owner-earnings.
The business collapsed under the weight of its own leverage and opaque governance. Despite rapid revenue growth, the negative net margins never turned positive as the company remained a price-taker in a commoditized market. The heavy reliance on related-party transactions eventually masked a fundamental lack of independent viability, and when the credit cycle tightened, the high debt-to-equity ratio and weak interest coverage led to a liquidity crunch. The preferential allotments to promoters diluted minority shareholders into oblivion while failing to produce actual owner-earnings.
RichFakir rates Raaj Medisafe India Ltd's business quality as mediocre — 44/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Raaj Medisafe India Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Raaj Medisafe India Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Raaj Medisafe India Ltd's fair value is about ₹34 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →